Monoclonal antibodies against cd30 lacking in fucosyl residues
AssigneeMedarex, Inc.
InventorsJosephine M. CARDARELLI, Amelia Nancy BLACK
Life of this patent
Estimating the term…
Abstract
The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
Claims10
A method of inhibiting growth or activity of CD30+ cells comprising contacting the cells with a defucosylated anti-CD30 antibody under conditions sufficient to induce antibody-dependent cellular cytoxicity (ADCC) of the cells.
Dependencies are inferred from the claim text.